Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) PT at $54.94

Intellia Therapeutics, Inc. (NASDAQ:NTLA) has been assigned an average recommendation of “Moderate Buy” from the eighteen analysts that are presently covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $52.81.

A number of equities analysts have recently issued reports on the company. Chardan Capital increased their target price on Intellia Therapeutics from $88.00 to $91.00 and gave the stock a “buy” rating in a report on Monday, November 18th. Robert W. Baird reduced their target price on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Citigroup dropped their target price on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. StockNews.com upgraded shares of Intellia Therapeutics to a “sell” rating in a research report on Friday, November 8th. Finally, The Goldman Sachs Group dropped their price objective on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating for the company in a report on Friday, October 25th.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA opened at $10.20 on Friday. The firm’s 50-day moving average is $13.77 and its 200-day moving average is $18.96. Intellia Therapeutics has a 52-week low of $9.93 and a 52-week high of $34.87. The company has a market cap of $1.04 billion, a price-to-earnings ratio of -1.87 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.37) by $0.03. The business had revenue of $9.10 million for the quarter, compared to the consensus estimate of $8.28 million. Intellia Therapeutics’s revenue was down 24.1% on a year-over-year basis. During the same period in the previous year, the business posted ($1.38) earnings per share. Equities analysts predict that Intellia Therapeutics will post -5.12 EPS for the current year.

Insider Buying and Selling

In related news, CEO John M. Leonard sold 26,807 shares of the company’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the sale, the chief executive officer now owns 941,115 shares in the company, valued at approximately $11,462,780.70. This represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders sold a total of 28,735 shares of company stock valued at $349,909 over the last ninety days. Insiders own 3.20% of the company’s stock.

Institutional Trading of Intellia Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its holdings in Intellia Therapeutics by 763.5% during the second quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock valued at $39,000 after purchasing an additional 1,550 shares during the period. Eastern Bank acquired a new position in shares of Intellia Therapeutics in the 3rd quarter valued at $41,000. Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at $54,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Intellia Therapeutics by 27.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,674 shares of the company’s stock valued at $77,000 after buying an additional 794 shares in the last quarter. Finally, KBC Group NV raised its stake in Intellia Therapeutics by 37.3% during the 3rd quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after buying an additional 1,020 shares during the period. 88.77% of the stock is owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.